Rheumatic diseases are erroneously believed to be the disease of the elderly, but a large number of young people too are affected by them. Dr. Gurvinder Singh Sawhney – Senior Consultant, Orthopaedics and Joint Replacement at Nanavati Hospital, gives us a perspective and suggests aggressive treatment strategies to manage flare-ups.
Rheumatic or musculoskeletal diseases are considered the aches and pains of the ageing, but there are several disorders prevalent even among young people. Which are…
![](/sites/default/files/styles/max_325x325/public/Resouces/images/Rheumatoid_arthritis%5B1%5D_1.jpg?itok=UsHz4kJi)
Tofacitinib (Xeljanz®) is the first of a unique class of oral kinase inhibitors to be FDA approved for the treatment of rheumatoid arthritis (RA). Tofacitinib is a selective inhibitor of Janus kinase (JAK) enzymes. these enzymes mediate signaling for several important cytokines that cause the inflammation in Rheumatoid Arthritic patients.
Condition
Changed
Sat, 09/06/2014 - 10:22